What is Zepatier?
Zepatier is anprescription medicine approved by the U.S. (FDA) for the treatment of chronic (HCV) in adults who meet certain requirements, as determined by a health care provider.
HCV can be an What is an Opportunistic Infection? fact sheet.(OI) of HIV. An OI is an that occurs more frequently or is more severe in people with weakened immune systems—such as people with HIV—than in people with healthy immune systems. To learn more about OIs, read the HIVinfo
To learn how HIV and HCV are connected, read the HIVinfo HIV and Hepatitis C fact sheet. The fact sheet includes information about HCV , prevention, and treatment.
How is Zepatier used in people with HIV?
The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV reference the AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C, which includes recommendations on the use of Zepatier to treat acute and chronic HCV infection in people with HIV.
The recommended uses may not always be consistent with FDA-approved uses of Zepatier. See the AASLD-IDSA HCV Guidelines for complete information on recommended uses of Zepatier in adults with HIV. Zepatier may have other recommended uses not listed above.
What should I tell my health care provider before taking Zepatier?
Before taking Zepatier, tell your health care provider:
- If you are allergic to any of the medicines in Zepatier (elbasvir or grazoprevir) or any other medicines.
- About any medical conditions you have or have had, especially:
- problems, including (HBV)
- Liver transplant
- If you have ever taken any medicine for HCV infection.
- About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take pills.
- If you are pregnant or plan to become pregnant. Talk to your health care provider about the risks and benefits of taking Zepatier during pregnancy. Pregnancy should be avoided during combination treatment with Zepatier and ribavirin and for 6 months after completion of the treatment. The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV may include other recommendations on the use of Zepatier during pregnancy. Please refer to these guidelines for additional information.
- If you are breastfeeding or plan to breastfeed. For women with HIV in the United States, the Guideline does not recommend breastfeeding. Before your baby is born, or if you are already breastfeeding, talk to your health care provider to discuss alternative options for feeding your baby.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products (including St. John's wort) you are taking or plan to take. Zepatier may affect the way other medicines or products work, and other medicines or products may affect how Zepatier works. Ask your health care provider if there are interactions between Zepatier and the other medicines you take.
Ask your health care provider about possible side effects from Zepatier. Your health care provider will tell you what to do if you have side effects.
How should I take Zepatier?
Take Zepatier according to your health care provider’s instructions. Your health care provider will tell you how much Zepatier to take and when to take it. Before you start Zepatier and each time you get a refill, read any printed information that comes with your medicine.
How should Zepatier be stored?
- Store Zepatier at room temperature, 68°F to 77°F (20°C to 25°C).
- Keep Zepatier in the container that it came in and keep the container tightly closed.
- Do not use Zepatier if the original seal over the container opening is broken or missing.
- Throw away Zepatier that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep Zepatier and all medicines out of reach of children.
Where can I find more information about Zepatier?
- Recommendations on the HIV-related uses of Zepatier, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, prepared by the , the , and the HIV Medicine Association of the Infectious Diseases Society of America.
- Recommendations on the HIV-related uses of Zepatier, from the HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C, prepared by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.
- This Patient Version drug summary is based on the following FDA label(s): Tablet (film coated). The Patient Counseling Information section of the label includes information for people taking Zepatier.
- Zepatier-related research studies, from
Last Reviewed: November 17, 2021